(Q37804687)

23 August 2017

The importance of new companies for drug discovery: origins of a decade of new drugs (English)

1 reference

23 August 2017

1 reference

Robert Kneller

1

1 reference

23 August 2017

29 October 2010

1 reference

Nature Reviews Drug Discovery

23 August 2017

1 reference

23 August 2017

9

1 reference

23 August 2017

11

1 reference

23 August 2017

867-882

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd3251

23 August 2017

0 references

cites work

Biotech drugs blaze a trail

1 reference

Lessons from 60 years of pharmaceutical innovation

31 March 2020

1 reference

31 March 2020

The origins of new drugs

1 reference

National origins of new drugs

31 March 2020

1 reference

Adopting orphan drugs--two dozen years of treating rare diseases.

31 March 2020

1 reference

Japan. Older scientists win majority of funding

31 March 2020

1 reference

Science education. And then there was one

31 March 2020

1 reference

2004 approvals: the demise of the blockbuster?

31 March 2020

1 reference

Pharma pursues novel models for academic collaboration

31 March 2020

1 reference

A historical sketch of the discovery and development of HIV-1 integrase inhibitors

31 March 2020

1 reference

Rebuilding the R&D engine in big pharma.

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21031002

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Richard Whitley, Jochen Gläser (eds.), The Changing Governance of the Sciences. The Advent of Research Evaluation Systems. Sociology of the Sciences Yearbook: Springer, Dordrecht, 2007, 26 pp.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21031002

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRD3251

1 reference

23 August 2017

1 reference

PubMed ID

21031002